Sihui Zhu Lijuan Bian Jia Lv Baorui Liu Jie Shen
10.3389/fimmu.2021.788629
Front Immunol
2021 Dec 23;12:788629.
cystitis immune-related adverse events intrahepatic cholangiocarcinoma programmed cell death-ligand 1 antibody programmed death-1 antibody
CC BY
https://pubmed.ncbi.nlm.nih.gov/35003107/
Antibodies, Monoclonal, Humanized / adverse effects Bile Duct Neoplasms / drug therapy Cholangiocarcinoma / drug therapy Cystitis / chemically induced Immune Checkpoint Inhibitors / adverse effects Nivolumab / adverse effects
Antibodies, Monoclonal, Humanized / adverse effects Bile Duct Neoplasms / drug therapy Cholangiocarcinoma / drug therapy Cystitis / chemically induced Immune Checkpoint Inhibitors / adverse effects Nivolumab / adverse effects Case Reports Research Support, Non-U.S. Gov't B7-H1 Antigen / antagonists & inhibitors B7-H1 Antigen / immunology Bile Duct Neoplasms / immunology Cholangiocarcinoma / immunology Cystitis / diagnosis Cystitis / drug therapy Cystitis / immunology Humans Male Middle Aged Programmed Cell Death 1 Receptor / antagonists & inhibitors Programmed Cell Death 1 Receptor / immunology Steroids / therapeutic use Treatment Outcome Antibodies, Monoclonal, Humanized B7-H1 Antigen CD274 protein, human Immune Checkpoint Inhibitors PDCD1 protein, human Programmed Cell Death 1 Receptor Steroids Nivolumab atezolizumab
PMC8733335
35003107
A Case Report of Non-Bacterial Cystitis Caused by Immune Checkpoint Inhibitors
2021